Sunday, 15 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· July 3, 2026

CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

View original at globenewswire.com
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS BANQUP GROUP Public limited liability company (“naamloze vennootschap” / “société anonyme“) under Belgian law Registered office at Avenue Reine Astrid 92A, 1310 La Hulpe, Belgium Company number 0886.277.617 Register of Legal Entities Walloon Brabant…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Proposal to grant the Board of Directors a new authorised capital authorisation of up to EUR 15,000,000, valid for three years from publication in the Belgian Official Gazette.

    60% confidence
  • Proposal to adopt a Dutch translation of the Articles of Association to comply with applicable language legislation given the Company's active establishments in the Flemish Region.

    60% confidence
  • Proposal to grant powers of attorney to each director, the officiating notary, and to Hilde Debontridder and Mathias Baert for implementation of resolutions and Crossroads Bank for Enterprises registration.

    60% confidence
  • Proposal to amend Article 1 of the Articles of Association to update the company's email address to info@banqup.com and website to www.banqup.com, following the company name change decided on 20 May 2025.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com